BACKGROUND AND PURPOSE: To report the outcome of patients with brain metastases from solid tumors treated with whole brain radiotherapy (WBRT) in a single institution. Given the high proportion of melanoma patients, a secondary aim was to compare our outcomes for patients with melanoma to those with other cancers. PATIENTS AND METHODS: A retrospective audit identified 474 patients treated between January 1983 and December 1999. Survival was calculated using the Kaplan-Meier method. Cox regression modeling was used for multivariate analysis. RESULTS: Four hundred and fifty nine patients have died from their disease. The median survival was 4.1 months for the whole group and 3.6 months for the 42% of patients with melanoma. The 1 and 2 year survival was 15 and 5%. Six patients lived beyond 5 years. 105 of 186 patients with a single brain metastasis underwent surgery plus WBRT, and 81 received WBRT alone. Median survival was 8 and 4 months, respectively, (P<0.0001). 30 Gy in 10 fractions was used more commonly in the early part of the study compared to 20 Gy in 5 fractions more recently. There was no difference in survival by time period. CONCLUSIONS: The survival in this series was comparable to other studies. Performance status, resection, dose, and the presence of extracranial disease appeared to be significant prognostic factors. The survival for the large number of patients with melanoma did not differ from the rest of the cohort.
BACKGROUND AND PURPOSE: To report the outcome of patients with brain metastases from solid tumors treated with whole brain radiotherapy (WBRT) in a single institution. Given the high proportion of melanomapatients, a secondary aim was to compare our outcomes for patients with melanoma to those with other cancers. PATIENTS AND METHODS: A retrospective audit identified 474 patients treated between January 1983 and December 1999. Survival was calculated using the Kaplan-Meier method. Cox regression modeling was used for multivariate analysis. RESULTS: Four hundred and fifty nine patients have died from their disease. The median survival was 4.1 months for the whole group and 3.6 months for the 42% of patients with melanoma. The 1 and 2 year survival was 15 and 5%. Six patients lived beyond 5 years. 105 of 186 patients with a single brain metastasis underwent surgery plus WBRT, and 81 received WBRT alone. Median survival was 8 and 4 months, respectively, (P<0.0001). 30 Gy in 10 fractions was used more commonly in the early part of the study compared to 20 Gy in 5 fractions more recently. There was no difference in survival by time period. CONCLUSIONS: The survival in this series was comparable to other studies. Performance status, resection, dose, and the presence of extracranial disease appeared to be significant prognostic factors. The survival for the large number of patients with melanoma did not differ from the rest of the cohort.
Authors: Brian A Wall; Lumeng J Yu; Atif Khan; Bruce Haffty; James S Goydos; Suzie Chen Journal: Pigment Cell Melanoma Res Date: 2014-11-28 Impact factor: 4.693
Authors: Shaheenah Dawood; Ana M Gonzalez-Angulo; Constance Albarracin; Tse Kuan Yu; Gabriel N Hortobagyi; Thomas A Buchholz; Wendy A Woodward Journal: Cancer Date: 2010-07-01 Impact factor: 6.860
Authors: Rupert Bartsch; Andrea Rottenfusser; Catharina Wenzel; Karin Dieckmann; Ursula Pluschnig; Gabriela Altorjai; Margaretha Rudas; Robert M Mader; Richard Poetter; Christoph C Zielinski; Guenther G Steger Journal: J Neurooncol Date: 2007-06-08 Impact factor: 4.130